Information Provided By: 
Fly News Breaks for May 23, 2018
ESPR
May 23, 2018 | 14:00 EDT
JMP Securities analyst Jason Butler said the results of the third of Esperion's four Phase 3 trials evaluating bempedoic acid for the treatment of elevated LDL-C looked "solid" and "clearly clinically significant." The safety profile was "clean" and consistent with prior trials, added Butler, who maintains an Outperform rating and $153 price target on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
